Phase II Study of Maintenance Therapy With Decitabine (NSC 127716, IND 50733) Following Standard Induction and Cytogenetic Risk-Adapted Intensification in Previously Untreated Patients With AML less than 60 Years.

Trial Profile

Phase II Study of Maintenance Therapy With Decitabine (NSC 127716, IND 50733) Following Standard Induction and Cytogenetic Risk-Adapted Intensification in Previously Untreated Patients With AML less than 60 Years.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Decitabine (Primary) ; Busulfan; Cytarabine; Daunorubicin; Etoposide; Filgrastim
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 19 Jul 2012 Planned end date changed from 1 Aug 2007 to 1 Jan 2100 as reported by ClinicalTrials.gov. (NCT01647074)
    • 19 Jul 2012 Planned end date changed from 1 Aug 2007 to 1 Jan 2100 as reported by ClinicalTrials.gov. (NCT01647074)
    • 11 Sep 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top